81 related articles for article (PubMed ID: 19965647)
1. The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA.
Burnett AK; Hills RK; Green C; Jenkinson S; Koo K; Patel Y; Guy C; Gilkes A; Milligan DW; Goldstone AH; Prentice AG; Wheatley K; Linch DC; Gale RE
Blood; 2010 Feb; 115(5):948-56. PubMed ID: 19965647
[TBL] [Abstract][Full Text] [Related]
2. Disease-stabilizing treatment based on all-trans retinoic acid and valproic acid in acute myeloid leukemia - identification of responders by gene expression profiling of pretreatment leukemic cells.
Reikvam H; Hovland R; Forthun RB; Erdal S; Gjertsen BT; Fredly H; Bruserud Ø
BMC Cancer; 2017 Sep; 17(1):630. PubMed ID: 28877686
[TBL] [Abstract][Full Text] [Related]
3. Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial.
Serve H; Krug U; Wagner R; Sauerland MC; Heinecke A; Brunnberg U; Schaich M; Ottmann O; Duyster J; Wandt H; Fischer T; Giagounidis A; Neubauer A; Reichle A; Aulitzky W; Noppeney R; Blau I; Kunzmann V; Stuhlmann R; Krämer A; Kreuzer KA; Brandts C; Steffen B; Thiede C; Müller-Tidow C; Ehninger G; Berdel WE
J Clin Oncol; 2013 Sep; 31(25):3110-8. PubMed ID: 23897964
[TBL] [Abstract][Full Text] [Related]
4. The NPM1 mutation type has no impact on survival in cytogenetically normal AML.
Pastore F; Greif PA; Schneider S; Ksienzyk B; Mellert G; Zellmeier E; Braess J; Sauerland CM; Heinecke A; Krug U; Berdel WE; Buechner T; Woermann B; Hiddemann W; Spiekermann K
PLoS One; 2014; 9(10):e109759. PubMed ID: 25299584
[TBL] [Abstract][Full Text] [Related]
5. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.
Döhner H; Estey E; Grimwade D; Amadori S; Appelbaum FR; Büchner T; Dombret H; Ebert BL; Fenaux P; Larson RA; Levine RL; Lo-Coco F; Naoe T; Niederwieser D; Ossenkoppele GJ; Sanz M; Sierra J; Tallman MS; Tien HF; Wei AH; Löwenberg B; Bloomfield CD
Blood; 2017 Jan; 129(4):424-447. PubMed ID: 27895058
[TBL] [Abstract][Full Text] [Related]
6. Randomized phase-III study of low-dose cytarabine and etoposide + /- all-trans retinoic acid in older unfit patients with NPM1-mutated acute myeloid leukemia.
Schlenk RF; Weber D; Krzykalla J; Kindler T; Wulf G; Hertenstein B; Salih HR; Südhoff T; Krauter J; Martens U; Wessendorf S; Runde V; Tischler HJ; Bentz M; Koller E; Heuser M; Thol F; Benner A; Ganser A; Döhner K; Döhner H
Sci Rep; 2023 Sep; 13(1):14809. PubMed ID: 37684299
[TBL] [Abstract][Full Text] [Related]
7. Homoharringtonine-Based Induction Regimen Improved the Remission Rate and Survival Rate in Chinese Childhood AML: A Report From the CCLG-AML 2015 Protocol Study.
Li J; Gao J; Liu A; Liu W; Xiong H; Liang C; Fang Y; Dai Y; Shao J; Yu H; Wang L; Wang L; Yang L; Yan M; Zhai X; Shi X; Tian X; Ju X; Chen Y; Wang J; Zhang L; Liang H; Chen S; Zhang J; Cao H; Jin J; Hu Q; Wang J; Wang Y; Zhou M; Han Y; Zhang R; Zhao W; Wang X; Lin L; Zhang R; Gao C; Xu L; Zhang Y; Fan J; Wu Y; Lin W; Yu J; Qi P; Huang P; Peng X; Peng Y; Wang T; Zheng H;
J Clin Oncol; 2023 Nov; 41(31):4881-4892. PubMed ID: 37531592
[TBL] [Abstract][Full Text] [Related]
8. The Promise of Retinoids in the Treatment of Cancer: Neither Burnt Out Nor Fading Away.
Nagai Y; Ambinder AJ
Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509198
[TBL] [Abstract][Full Text] [Related]
9. Next-Generation Sequencing-Based Genomic Profiling of Children with Acute Myeloid Leukemia.
Krizsán S; Péterffy B; Egyed B; Nagy T; Sebestyén E; Hegyi LL; Jakab Z; Erdélyi DJ; Müller J; Péter G; Csanádi K; Kállay K; Kriván G; Barna G; Bedics G; Haltrich I; Ottóffy G; Csernus K; Vojcek Á; Tiszlavicz LG; Gábor KM; Kelemen Á; Hauser P; Gaál Z; Szegedi I; Ujfalusi A; Kajtár B; Kiss C; Matolcsy A; Tímár B; Kovács G; Alpár D; Bödör C
J Mol Diagn; 2023 Aug; 25(8):555-568. PubMed ID: 37088137
[TBL] [Abstract][Full Text] [Related]
10. All-trans retinoic acid improves NSD2-mediated RARα phase separation and efficacy of anti-CD38 CAR T-cell therapy in multiple myeloma.
Peng Z; Wang J; Guo J; Li X; Wang S; Xie Y; Jiang H; Wang Y; Wang M; Hu M; Li Q; Wang Y; Mi JQ; Liu Z
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36918219
[TBL] [Abstract][Full Text] [Related]
11. All-trans retinoic acid enhances the cytotoxic effect of decitabine on myelodysplastic syndromes and acute myeloid leukaemia by activating the RARα-Nrf2 complex.
Wang L; Zhang Q; Ye L; Ye X; Yang W; Zhang H; Zhou X; Ren Y; Ma L; Zhang X; Mei C; Xu G; Li K; Luo Y; Jiang L; Lin P; Zhu S; Lang W; Wang Y; Shen C; Han Y; Liu X; Yang H; Lu C; Sun J; Jin J; Tong H
Br J Cancer; 2023 Feb; 128(4):691-701. PubMed ID: 36482192
[TBL] [Abstract][Full Text] [Related]
12. Vitamin D Derivatives in Acute Myeloid Leukemia: The Matter of Selecting the Right Targets.
Marcinkowska E
Nutrients; 2022 Jul; 14(14):. PubMed ID: 35889808
[TBL] [Abstract][Full Text] [Related]
13. All-trans retinoic acid induces differentiation in primary acute myeloid leukemia blasts carrying an inversion of chromosome 16.
Dembitz V; Lalic H; Tomic B; Smoljo T; Batinic J; Dubravcic K; Batinic D; Bedalov A; Visnjic D
Int J Hematol; 2022 Jan; 115(1):43-53. PubMed ID: 34546543
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic Use of Valproic Acid and All-Trans Retinoic Acid in Acute Myeloid Leukemia-Literature Review and Discussion of Possible Use in Relapse after Allogeneic Stem Cell Transplantation.
Bruserud Ø; Tsykunova G; Hernandez-Valladares M; Reikvam H; Tvedt THA
Pharmaceuticals (Basel); 2021 May; 14(5):. PubMed ID: 34063204
[TBL] [Abstract][Full Text] [Related]
15. IGFBP7 activates retinoid acid-induced responses in acute myeloid leukemia stem and progenitor cells.
van Gils N; Verhagen HJMP; Rutten A; Menezes RX; Tsui ML; Vermue E; Dekens E; Brocco F; Denkers F; Kessler FL; Ossenkoppele GJ; Janssen JJWM; Smit L
Blood Adv; 2020 Dec; 4(24):6368-6383. PubMed ID: 33351133
[TBL] [Abstract][Full Text] [Related]
16. A Phase 1 Study of IRX195183, a RARα-Selective CYP26 Resistant Retinoid, in Patients With Relapsed or Refractory AML.
Ambinder AJ; Norsworthy K; Hernandez D; Palau L; Paun B; Duffield A; Chandraratna R; Sanders M; Varadhan R; Jones RJ; Douglas Smith B; Ghiaur G
Front Oncol; 2020; 10():587062. PubMed ID: 33194741
[TBL] [Abstract][Full Text] [Related]
17. Differentiation therapy of myeloid leukemia: four decades of development.
Madan V; Koeffler HP
Haematologica; 2021 Jan; 106(1):26-38. PubMed ID: 33054125
[TBL] [Abstract][Full Text] [Related]
18.
Nguyen CH; Grandits AM; Vassiliou GS; Staber PB; Heller G; Wieser R
Biomedicines; 2020 Sep; 8(10):. PubMed ID: 32998330
[No Abstract] [Full Text] [Related]
19.
Nguyen CH; Grandits AM; Purton LE; Sill H; Wieser R
Cell Cycle; 2020 Oct; 19(20):2573-2588. PubMed ID: 32900260
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
